Introduction {#sec1}
============

Colorectal cancer (CRC) is regarded as the third most frequent malignant tumour worldwide, and its rate of mortality has increased over the past several decades due to recurrence and metastasis \[[@cit0001]\]. Despite advances in cancer treatments and management of CRC, prognostic biomarkers remain a promising way to predict the outcome of cancer \[[@cit0002]\]. Currently, some prognostic factors, such as tumour TNM stage, cell differentiation grade, and vascular invasion, have been widely utilised as the most accurate predictors of tumour recurrence and prognosis \[[@cit0003]\]. However, the survival outcome varies widely even in patients with the same TNM stage and tumour differentiation grade. Therefore, to estimate more specific oncological outcomes, novel prognostic markers are also required.

Strong evidence has confirmed that systemic inflammatory response is known to play a vital role in human cancer development and progression \[[@cit0004]\]. Tumors are closely related to inflammation. Inflammation is an essential component of the tumour microenvironment, and the changes in inflammatory cells might influence tumour progression, such as neoplastic cell proliferation, migration, invasion, collapse of anti-tumour immunity, metastasis, and so forth \[[@cit0005], [@cit0006]\]. Accumulating evidence shows that the peripheral neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have been widely proposed as prognostic factors for many malignancies such as gastric cancer \[[@cit0007]\], nasopharyngeal carcinoma \[[@cit0008]\], liver cancer \[[@cit0009]\], and especially colorectal cancer \[[@cit0010]\]. Moreover, it is likely that the tumour microenvironment as well as systemic inflammatory response might be changed because of surgery \[[@cit0011]\]. However, only a few studies have assessed the relationship between dynamic changes of these perioperative inflammatory markers and survival prognosis in such patients.

Aim {#sec2}
===

In the present study, we hypothesised that both predictors are associated with prognostic survival in CRC patients who have undergone curative surgery. Furthermore, we compared perioperative changes to evaluate the prognostic significance of patients' survival.

Material and methods {#sec3}
====================

This study was conducted according to the Declaration of Helsinki and was approved by our Hospital. Written, informed consent was obtained from all individual participants included in the study.

Patient selection {#sec3.1}
-----------------

A total of 183 CRC patients treated with curative surgery at the Department of Colorectal Surgery in our hospital from January 2007 to January 2013 were reviewed. Patients are excluded if they suffered from infection, haematological diseases, hyperpyrexia, renal dysfunction, diabetes mellitus, and other acute or chronic diseases, or if they had received previous chemotherapy, radiotherapy, or other targeted therapy. Postoperative follow-ups were generally performed by letter and by telephone interview every 3--6 months until death or 5 years and were ended after January 1, 2018.

Perioperative model of NLR and PLR {#sec3.2}
----------------------------------

Preoperative blood samples were obtained prior to the surgical operation. The median interval between pre- and postoperative blood tests was 14 days. For the calculation of the NLR and PLR, NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count, and PLR was also conducted in the same way. The cut-off value for haematological profiles was determined using the receiver operating characteristic (ROC) curve analysis. According to the cut-off value, all patients were divided into four groups: HH, patients with both high preoperative and postoperative values; HL, patients with high preoperative and low postoperative values; LH, patients with low preoperative and high postoperative values; and LL, both low preoperative and postoperative values. Medical records were assimilated with respect to the patients' age, sex, and clinicopathological characteristics (such as location, size, histological type, TNM stage, invasion, and lymph node).

Statistical analysis {#sec3.3}
--------------------

The end points of this study were recurrence-free survival (RFS), which was defined as the time from the first day of palliative operation to the disease progression or recurrence, and overall survival (OS), which was defined as the time from the first day of palliative operation to death by any cause or to the last follow-up. ROC analysis determined the optimal cut-off value as a predictive marker for OS and RFS. The association between the clinicopathological characteristics and perioperative change of the four groups were compared using the χ^2^ test or Fisher's exact probability test. The survival curves were generated using the Kaplan-Meier method, and the differences were compared using the log-rank test. The univariate analysis assessed the prognostic factors, and multivariate analysis (Cox's proportional-hazards regression model) evaluated the independent factors for survival prognosis. *P*-values \< 0.05 were considered statistically significant. The statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).

Results {#sec4}
=======

Patient demographics and clinicopathological characteristics {#sec4.1}
------------------------------------------------------------

[Table I](#t0001){ref-type="table"} shows the clinicopathological characteristics of the 183 patients in the study. The female-to-male ratio was 85:98, and the median age was 69 years, ranging from 45 to 79 years. Patients predominantly suffered from rectal cancer (64.48%), and 58.47% of patients presented tumour size ≥ 3 cm. The clinical TNM stage revealed the pathological diagnoses as follows: 37 patients with stage I, 67 patients with stage II, 49 patients with stage III, and 30 patients with stage IV. Moreover, the histological grade revealed 121 patients in G1-2 and 62 patients in G3-4. In terms of cancer invasion, high grades (T1-2) constituted 94 patients, and the other grades (T3-4) constituted 99 patients. A total of 71 patients presented lymph node with negative tumour (N0), while 112 patients were positive, and 109 patients received postoperative adjuvant chemotherapy. ROC analysis could calculate the sensitivity and specificity levels of NLR and PLR as survival estimation predictors, as shown in [Figure 1](#f0001){ref-type="fig"}. For RFS, pre- and post- NLR showed a larger AUC than pre- or post- NLR. Moreover, the predictor of PLR showed similar results. Regarding OS, pre- and post-NLR/PLR was superior to the pre- or post-NLR/PLR. The optimal cut-off values of perioperative NLR and PLR were pre-2.94, post-4.32 and pre-184.29, post-212.37, respectively. Furthermore, we divided the patients into four groups according to these perioperative cut-off values. [Table I](#t0001){ref-type="table"} also shows the distribution of patients in these four groups. Patients with higher cancer stage, poorer differentiation, and greater lymph node metastasis were significantly associated with perioperative NLR or PLR (all *p* \< 0.05). Conversely, no difference was observed in age, gender, tumour location, size, and adjuvant chemotherapy (all *p* \> 0.05).

###### 

Comparison between groups stratified by perioperative changes and patients' clinicopathological

  Characteristics          Total *N* = 183   NLR   *P*-value   PLR   *P*-value                               
  ------------------------ ----------------- ----- ----------- ----- ----------- ------- ---- ---- ---- ---- -------
  Age \[years\]:                             35    42          50    56          0.365   46   43   40   54   0.837
   \< 65                   74                16    18          15    25                  21   16   15   22   
   ≥ 65                    109               19    24          35    31                  25   27   25   32   
  Sex:                                                                           0.125                       0.622
   Female                  85                12    16          28    29                  22   22   15   26   
   Male                    98                23    26          22    27                  24   21   25   28   
  Location:                                                                      0.095                       0.114
   Colon                   65                12    19          21    13                  12   17   11   25   
   Rectal                  118               23    23          29    43                  34   26   29   29   
  Tumour size \[cm\]:                                                            0.409                       0.639
   \< 3                    76                18    17          22    19                  20   21   14   21   
   ≥ 3                     107               17    25          28    37                  22   26   26   33   
  Cancer stage:                                                                  0.005                       0.012
   I--II                   104               27    24          21    22                  32   29   21   22   
   III--IV                 79                8     18          19    34                  14   14   19   32   
  Cancer grade:                                                                  0.034                       0.008
   G1--2                   121               28    29          35    29                  35   32   27   26   
   G3--4                   62                7     13          15    27                  10   11   13   28   
  Tumour invasion:                                                               0.007                       0.001
   T1--2                   94                22    23          23    16                  32   21   15   16   
   T3--4                   99                13    19          27    40                  14   22   25   38   
  Lymph node:                                                                    0.004                       0.039
   N0                      71                21    19          18    13                  22   21   15   13   
   N+                      112               14    23          32    43                  24   22   25   41   
  Adjuvant chemotherapy:                                                         0.240                       0.239
   No                      74                9     19          23    23                  14   16   17   27   
   Yes                     109               26    23          27    33                  32   27   23   27   

NLR -- neutrophil-to-lymphocyte ratio, PLR -- platelet-to-lymphocyte ratio, LL-NLR/PLR -- low pre- + low post-NLR/PLR, LH-NLR/PLR -- low pre- + high post-NLR/PLR, HL-NLR/PLR -- high pre- + low post-NLR/PLR, HH-NLR/PLR -- high pre- + high post-NLR/PLR.

###### 

Comparison of area under ROC curves between NLR and PLR for RFS and OS. **A--C** -- RFS, **D** -- OS **E, F** -- OS

![](PG-14-38787-g001)
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Comparison between survival prognosis and perioperative changes {#sec4.2}
---------------------------------------------------------------

According to the follow-up period, 61 (33.33%) patients had recurrence: 22 patients presented local recurrence and 39 patients developed distant metastasis. Seventy-six (41.53%) patients died: 33 patients from tumour recurrence, one from chemotherapeutic toxicity, and the other patients due to unknown reasons. For prognosis of patients according to the Kaplan-Meier curve and log-rank test, the four groups (LL, LH, HL, and HH) stratified by perioperative changes had significantly different RFS and OS, as shown in [Figure 2](#f0002){ref-type="fig"} (all *p* \< 0.05). Thus, perioperative changes of NLR and PLR could effectively predict the prognostic survival of CRC patients in the present study.

![Kaplan-Meier curves showing RFS and OS. **A, B** -- Patients with higher perioperative change of NLR and PLR tended to have worse recurrence-free survival (all *p* \< 0.05). **C, D** -- Patients with higher perioperative change of NLR and PLR tended to have worse overall survival (all *p* \< 0.05)](PG-14-38787-g002){#f0002}

Prognostic variables for RFS and OS {#sec4.3}
-----------------------------------

With respect to all prognostic factors, [Tables II](#t0002){ref-type="table"} and [III](#t0003){ref-type="table"} showed the results of univariate and multivariate analysis of various parameters in terms of RFS and OS. Univariate analysis revealed that patients with high cancer stage, poorer differentiation grade, severer invasion and lymph node metastasis, no adjuvant chemotherapy, and greater perioperative change of NLR/PLR (HH, LH) were obviously associated with worse RFS and OS (all *p* \< 0.05). Although tumour location was significantly associated with poor OS (*p* \< 0.05), it was not related to RFS. Factors with *p* \< 0.05 in univariate analysis were conducted for further multivariate analysis. Patients with higher cancer stage, lymph node metastasis, and perioperative change of NLR/PLR (HH, LH) had significant association with poor prognosis of OS and RFS (all *p* \< 0.05). Simultaneously, it suggested that LH-NLR/PLR is a protective factor for survival (HR \< 1).

###### 

Univariate and multivariate analysis of factors associated with recurrence-free survival

  Characteristics          Univariate analysis   Multivariate analysis                                         
  ------------------------ --------------------- ----------------------- ---------- ----------- -------------- -------
  Age \[years\]:                                                                                               
   \< 65                   Reference                                                                           
   ≥ 65                    1.211                 0.911--2.126            0.450                                 
  Sex:                                                                                                         
   Female                  Reference                                                                           
   Male                    0.806                 0.454--1.432            0.464                                 
  Location:                                                                                                    
   Colon                   Reference                                                                           
   Rectal                  0.577                 0.325--1.024            0.060                                 
  Tumour size \[cm\]:                                                                                          
   \< 3                    Reference                                                Reference                  
   ≥ 3                     1.379                 0.969--1.853            0.012      0.811       0.312--1.642   0.311
  Cancer stage:                                                                                                
   I--II                   Reference                                                Reference                  
   III--IV                 3.096                 1.318--5.899            \< 0.001   3.104       1.291--5.916   0.001
  Cancer grade:                                                                                                
   G1--2                   Reference                                                Reference                  
   G3--4                   1.798                 1.007--3.209            0.012      1.484       0.972--2.134   0.079
  Tumour invasion:                                                                                             
   T1--2                   Reference                                                Reference                  
   T3--4                   2.277                 1.100--4.715            0.006      1.970       1.129--3.571   0.081
  Lymph node:                                                                                                  
   N0                      Reference                                                Reference                  
   N+                      2.371                 1.633--4.912            0.002      2.164       1.472--4.529   0.011
  Adjuvant chemotherapy:                                                                                       
   No                      Reference                                                Reference                  
   Yes                     1.896                 1.341--3.722            0.007      1.687       1.276--3.572   0.018
  NLR:                                                                                                         
   LL-NLR                  Reference                                                Reference                  
   LH-NLR                  1.976                 1.311--2.512            0.031      1.822       1.137--2.714   0.045
   HL-NLR                  1.791                 1.019--2.352            0.022      0.892       0.522--1.876   0.245
   HH-NLR                  2.768                 1.422--5.016            0.001      2.648       1.376--4.763   0.005
  PLR:                                                                                                         
   LL-PLR                  Reference                                                Reference                  
   LH-PLR                  1.867                 1.112--3.422            0.024      1.648       0.973--2.544   0.079
   HL-PLR                  1.822                 1.221--2.936            0.015      0.762       0.589--1.866   0.326
   HH-PLR                  2.399                 1.578--4.971            0.002      2.011       1.422--4.372   0.021

###### 

Univariate and multivariate analysis of factors associated with overall survival

  Characteristics          Univariate analysis   Multivariate analysis                                        
  ------------------------ --------------------- ----------------------- --------- ----------- -------------- -------
  Age \[years\]:                                                                                              
   \< 65                   Reference                                                                          
   ≥ 65                    1.065                 0.657--1.727            0.279                                
  Sex:                                                                                                        
   Female                  Reference                                                                          
   Male                    0.836                 0.520--1.343            0.458                                
  Location:                                                                                                   
   Colon                   Reference                                               Reference                  
   Rectal                  0.599                 0.372--0.966            0.035     0.664       0.386--1.143   0.140
  Tumour size \[cm\]:                                                                                         
   \< 3                    Reference                                               Reference                  
   ≥ 3                     0.520                 0.322--1.839            0.007     0.616       0.368--1.030   0.072
  Cancer stage:                                                                                               
   I--II                   Reference                                               Reference                  
   III--IV                 3.488                 1.305--5.879            \<0.001   3.112       1.194--5.682   0.001
  Cancer grade:                                                                                               
   G1--2                   Reference                                               Reference                  
   G3--4                   1.212                 0.746--3.029            0.009     1.048       0.672--2.876   0.026
  Tumour invasion:                                                                                            
   T1--2                   Reference                                               Reference                  
   T3--4                   2.467                 1.391--4.377            0.002     2.242       1.421--4.979   0.014
  Lymph node:                                                                                                 
   N0                      Reference                                               Reference                  
   N+                      2.302                 1.386--3.822            0.001     2.065       1.168--3.279   0.012
  Adjuvant chemotherapy:                                                                                      
   No                      Reference                                               Reference                  
   Yes                     2.146                 1.244--3.561            0.005     1.884       1.071--3.624   0.027
  NLR:                                                                                                        
   LL-NLR                  Reference                                               Reference                  
   LH-NLR                  1.071                 0.781--2.896            0.012     1.027       0.637--2.544   0.036
   HL-NLR                  1.791                 1.224--2.786            0.018     1.884       1.522--2.941   0.121
   HH-NLR                  2.894                 1.236--5.412            \<0.001   3.048       1.271--5.664   0.002
  PLR:                                                                                                        
   LL-PLR                  Reference                                               Reference                  
   LH-PLR                  1.276                 0.972--3.524            0.015     1.451       0.867--2.832   0.225
   HL-PLR                  1.443                 1.021--3.514            0.036     1.662       1.188--2.866   0.175
   HH-PLR                  2.678                 1.172--4.861            0.001     2.477       1.321--4.372   0.015

Discussion {#sec5}
==========

To our knowledge, this is the first study to evaluate the associations between perioperative changes of NLR and PLR and the postoperative outcome in patients with CRC, who underwent palliative resection of the primary tumour. Our results indicate that perioperative changes of NLR and PLR as biomarkers to predict prognosis would help to elucidate the survival rates in such patients.

Various studies have indicated that changes in immune cellular components in peripheral venous blood could reflect the inflammation status of the tumour, which is valuable in predicting survival prognosis \[[@cit0012], [@cit0013]\]. It is increasingly speculated that the inflammation and tumour are correlated, resulting in the establishment of novel biomarkers of cancer for the evaluation of the prognostic significance \[[@cit0014]\]. Reportedly, neutrophils reflect the status of the systematic inflammation and accelerate the remodelling of the extracellular matrix \[[@cit0015]\]. This, in turn, stimulates the tumour-cell proliferation, migration, and metastasis via the enzymatic actions, such as the release of reactive oxygen species (ROS), nitric oxide (NO), and anginas \[[@cit0016]\]. Moreover, neutrophilia activates the inflammatory response to promote the tumour growth by pro-angiogenic and growth factors \[[@cit0017]\]. Another study showed the lymphocyte infiltration response to the tumour. Increased lymphocytic reactions have been associated with a better outcome \[[@cit0018]\]. In addition, platelets could secrete cellular growth factors such as platelet-derived growth factor, vascular endothelial growth factor, transforming growth factor β, and platelet factor 4, followed by the stimulation of tumour angiogenesis and growth \[[@cit0019], [@cit0020]\]. Therefore, NLR and PLR represent the tumour-inflammatory response, which indicates the degree of tumour progression and contributes to the prediction of survival prognosis.

However, there is a great deal of risk and bias in using only one index for detection. For more comprehensive assessment of prognosis in this study, we use the combined preoperative and post-operative changes of both biomarkers to increase the predictive accuracy for survival compared with preoperative or postoperative ones alone. ROC analysis indicated that pre- and post-NLR/PLR were superior to the pre- or post-NLR/PLR for RFS and OS, respectively. The change of tumour status and surgical stress may affect systemic inflammation as well as oncological outcome \[[@cit0021]\]. It is conceivable that significant tumour reduction after surgery may lead to improvement of systemic inflammation as well as immunological response \[[@cit0022]\]. It is reported that the surgery itself promotes the release of tumour emboli and induces immunosuppression that favours the survival and progression of cancer \[[@cit0023]\]. We also found that the change in perioperative NLR/PLR was independently associated with elevated risk for RFS and OS. Simultaneously, it indicated that LH-NLR/PLR seems to be a protective factor for survival (HR \< 1). Although this stratification requires external validation, it may enable us to identify patients with risk or protective factors.

Besides perioperative NLR/PLR factors, cancer stage, lymph node, and adjuvant chemotherapy were also identified as robust prognostic indicators in the univariate and multivariate analysis, which is consistent with the results of previous studies \[[@cit0024], [@cit0025]\]. However, our study showed that tumour invasion and cancer grade were associated with poor prognosis in the univariate analysis but not in the multivariate analysis. Compared with previous prognostic indicators, this inflammatory biomarker has the advantage of being simple, easily available, economical, objective, and reproducible, and it could be measured at the beginning of chemotherapy treatment and monitored throughout the entire therapy period \[[@cit0026]\].

Nevertheless, our study has some limitations that should be mentioned. First, it is a retrospective investigation; thus, a potential bias in the selection of patients is inevitable. Second, surgery was performed by several surgeons, which possibly influenced oncological outcome. Finally, the current study lacked any evaluation of tumour-associated neutrophils and lymphocytes, which could cause different immune responses.

Conclusions {#sec6}
===========

The current study suggests that perioperative NLR/PLR might be a good predictor for prognosis in CRC patients undergoing curative surgery. It is recommended as a practical tool to assess the prognosis of RFS and OS. Thus, these findings provided an in-depth understanding of the patients, which could help guide a customised therapeutic strategy.
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